Table 2.
Characteristics of HIV-infected patients with tuberculosis (TB) aged ≥ 10 years (n=11,534) stratified by CD4 count.
| CD4 (cells/μL) | ALL (n=11,534) | <50 (n=2,061) | 50–99 (n=1,952) | 100–149 (n=1,704) | 150–199 (n=1,406) | 200–349 (n=2,501) | 350–499 (n=1,126) | ≥500 (n=784) |
|---|---|---|---|---|---|---|---|---|
| PROPORTION OF DIAGNOSES | 100.0% | 17.9% | 16.9% | 14.8% | 12.2% | 21.7% | 9.8% | 6.8% |
| GENDER | ||||||||
| Female | 6244 (54.1%) | 1011 (49.1%) | 940 (48.2%) | 915 (53.7%) | 795 (56.5%) | 1411 (56.4%) | 688 (61.1%) | 484 (61.7%) |
| AGE | ||||||||
| Median (IQR) | 34 (28–40) | 33 (29–40) | 34 (29–41) | 33 (28–40) | 34 (28–40) | 33 (28–40) | 33 (27–40) | 33 (27–40) |
| CATEGORY | ||||||||
| New | 8043 (69.7%) | 1507 (73.1%) | 1393 (73.4%) | 1213 (71.2%) | 986 (70.1%) | 1670 (66.8%) | 758 (67.3%) | 516 (65.8%) |
| Retreatment | 3491 (30.3%) | 554 (26.9%) | 559 (28.6%) | 491 (28.8%) | 420 (29.8%) | 831 (33.2%) | 368 (32.7%) | 268 (34.2%) |
| SITE | ||||||||
| PTB | 8693 (75.4%) | 1464 (71.0%) | 1406 (72.0%) | 1250 (73.4%) | 1072 (76.2%) | 1932 (77.3%) | 916 (81.4%) | 653 (83.3%) |
| EPTB | 2083 (18.1%) | 361 (17.5%) | 381 (19.5%) | 330 (19.4%) | 259 (18.4%) | 468 (18.7%) | 173 (15.4%) | 111 (14.2%) |
| PTB + EPTB | 758 (6.6%) | 236 (11.5%) | 165 (8.5%) | 124 (7.3%) | 75 (5.3%) | 101 (4.0%) | 37 (3.3%) | 20 (2.6%) |
| SITE OF EPTB‡ | ||||||||
| Pleural | 1212 (42.7%) | 171 (29.6%) | 230 (42.1%) | 213 (46.9%) | 153 (45.8%) | 285 (50.1%) | 101 (48.1%) | 59 (45.0%) |
| Miliary | 444 (15.6%) | 152 (25.5%) | 103 (18.9%) | 76 (16.7%) | 36 (10.8%) | 54 (9.5%) | 17 (8.1%) | 6 (4.6%) |
| Lymph nodes | 331 (11.7%) | 72 (12.1%) | 60 (11.0%) | 51 (11.2%) | 48 (14.4%) | 68 (12.0%) | 17 (8.1%) | 15 (11.5%) |
| Meningitis | 277 (9.8%) | 52 (8.7%) | 42 (7.7%) | 33 (7.3%) | 28 (8.4%) | 65 (11.4%) | 36 (17.1%) | 21 (16.0%) |
| Bones / joints | 85 (3.0%) | 23 (3.9%) | 9 (1.7%) | 11 (2.4%) | 18 (5.4%) | 12 (2.1%) | 8 (3.8%) | 4 (3.1%) |
| Genito-urinary | 20 (0.7%) | 8 (1.3%) | 5 (0.9%) | 3 (0.7%) | 1 (0.3%) | 2 (0.4%) | 0 (0.0%) | 1 (0.8%) |
| Not specified | 517 (18.2%) | 133 (22.3%) | 104 (19.1%) | 73 (16.1%) | 55 (16.5%) | 94 (16.5%) | 33 (15.7%) | 25 (19.1%) |
| LABORATORY CONFIRMATION | ||||||||
| Smear + | 3798 (32.9%) | 684 (33.2%) | 578 (29.6%) | 496 (29.1%) | 431 (30.7%) | 838 (33.5%) | 460 (40.9%) | 311 (39.7%) |
| Smear − Culture + | 2394 (20.8%) | 345 (16.7%) | 387 (19.8%) | 386 (22.7%) | 353 (25.1%) | 525 (21.0%) | 228 (20.3%) | 170 (21.7%) |
| No Confirmation | 5342 (46.3%) | 1032 (50.1%) | 987 (50.6%) | 822 (48.2%) | 622 (44.2%) | 1138 (45.5%) | 438 (38.9%) | 303 (38.6%) |
Data presented as number (%) or median (IQR). Column percentages are shown.
‡
Percentages shown for sites of EPTB reflect proportions of those with extra-pulmonary disease with or without concomitant PTB.
PTB = pulmonary TB; EPTB = extra-pulmonary TB; ART = antiretroviral therapy.